Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety

Yi-You Huang,Jinhui Deng,Yi-Jing Tian,Jinhao Liang,Xi Xie,Yue Huang,Jiaqi Zhu,Ziran Zhu,Qian Zhou,Xixin He,Hai-Bin Luo

DOI: https://doi.org/10.1021/acs.jmedchem.1c01085

IF: 8.039

2021-09-14

Journal of Medicinal Chemistry

Abstract:Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease, and its incidence rate is rapidly rising. However, effective therapies for the treatment of IPF are still lacking. Phosphodiesterase 4 (PDE4) inhibitors were reported to be potential anti-fibrotic agents, but their clinical use was hampered by side effects like emesis and nausea. Herein, structure-based hit-to-lead optimizations of natural mangostanin resulted in the novel and orally active PDE4 inhibitor 18a with potent inhibitory affinity (IC50 = 4.2 nM), favorable physico-chemical properties, and a different binding pattern from roflumilast. Emetic activity tests on dogs demonstrated that 18a cannot cause emesis even at an oral dose of 10 mg/kg, whereas rolipram had severe emetic effects at an oral dose of 1 mg/kg. Finally, the oral administration of 18a (10 mg/kg) exhibited comparable anti-pulmonary fibrosis effects with pirfenidone (150 mg/kg) in a bleomycin-induced IPF rat model, indicating its potential as a novel anti-IPF agent with improved safety.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c01085.Protein data bank of PDE4D-18a (PDB)Protein data bank of PDE4D-18c (PDB)1H NMR, 13C NMR, and high-resolution mass spectra; HPLC spectra data for the tested compounds; crystal data collection and refinement statistics of 18a; acute toxicity of 18a; and NO production inhibitory activity of 18a (PDF)Molecular formula strings and some data (CSV)This article has not yet been cited by other publications.

chemistry, medicinal